オプションチェーンは、Phathom Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Phathom Pharmaceuticalsの市場センチメントを評価します。.

Phathom Pharmaceuticals (NASDAQ:PHAT) 株価情報, オプションチェーン

PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

Barrington Research analyst Patrick Sholl maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Outperform and maintains $25 price target.

News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Marcus, Maintains $25 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Outperform and lowers the price target from $100 to $90.

Telsey Advisory Group Maintains Outperform on Best Buy Co, Lowers Price Target to $90

<ul>
<li>Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations</li>
<li>Successful completion of the pivotal Phase 3 study may support Biologics License Application, Priority Review, Full Approval, and Commercialization</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ)), (TSX:<a href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the presentation of positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.

BCTX

BriaCell Therapeutics To Highlight Survival And Clinical Benefit Data In Three Clinical Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting

Telsey Advisory Group analyst Dana Telsey downgrades Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) from Outperform to Market Perform and lowers the price target from $240 to $120.

Downgrades

DECK

Telsey Advisory Group Downgrades Deckers Outdoor to Market Perform, Lowers Price Target to $120

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $340 to $345.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $345

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and maintains $130 price target.

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Maintains $130 Price Target

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(3.20) per share. This is a 39.13 percent decrease over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $1.20 million by 14.08 percent. This is a 121.24 percent increase over sales of $466.00 thousand the same period last year.

Earnings

Earnings Misses

SLGL

Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate

D. Boral Capital analyst Jason Kolbert maintains Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Buy and lowers the price target from $15 to $10.

NNOX

D. Boral Capital Maintains Buy on Nano X Imaging, Lowers Price Target to $10

GSK's Blenrep (Belantamab Mafodotin) Received Positive Opinion Form The EUs CHMP For Treatment Of Relapsed Or Refractory Multiple Myeloma In Adults Aged 60+

PHUN

Phunware Unveils Hospitality AI Features To Enhance Mobile Guest Engagement, Plans Next-Gen App Innovation Talks

Bank of America Corporation Announced That It Will Redeem On June 12, 2025 All CHF375,000,000 Principal Amount Outstanding Of Its 0.2525% Senior Notes, Due June 12

Legal

BABA

Alibaba Concluded Some Products May Contain 3TG From Covered Countries, But Finds No Evidence The 3TG Financed Armed Groups

PPTA

Perpetua Resources Submits Formal Application To Export-Import Bank of the United States to Finance Stibnite Gold Project, Company Seeks $2B Financing; Aims To Boost U.S. Antimony Supply Amid Strategic Minerals Push

OKLO: 24% &#x7C; <a href="https://www.benzinga.com//node/45577517">Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.</a>
&nbsp;
BCAX: -36% &#x7C; <a href="https://www.benzinga.com//node/45576722">Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</a>
&nbsp;
IMMX: -20% &#x7C; <a href="https://www.benzinga.com//node/45577764">IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.</a>

Movers

Trading Ideas

BCAX

IMMX

OKLO

Market-Moving News for May 23rd

Memorandum aims to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure, fueling R&amp;D, talent development, and ecosystem growth.
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, today announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Science and Technology Information (KISTI), a leading national science and technology research institute and supercomputing center. The memorandum marks a significant expansion of IonQ's long standing relationship with South Korea's government, academic and industry sectors, aligning efforts intended to accelerate the national development of quantum science and industry.
Under the terms of the MoU, IonQ and KISTI will collaborate in four key areas: advanced infrastructure access, education, talent and knowledge exchange as well as collaboration to expand market opportunities. The two organizations will work together with the intent to introduce quantum systems into KISTI and plan to integrate these systems with KISTI's high-performance computing (HPC) infrastructure.
IonQ and KISTI also plan to collaborate on joint initiatives for talent upskilling including internships and training programs to strengthen the quantum computing research community in South Korea.

IONQ

IonQ Signs MoU With KISTI To Integrate IonQ's Quantum Technology Into South Korea's Computing Infrastructure, Fueling R&D, Talent Development, And Ecosystem Growth

HC Wainwright &amp; Co. analyst Yi Chen maintains Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and lowers the price target from $15 to $12.

KALA

HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $12

KDLY

KindlyMD Changes NASDAQ Ticker To 'NAKA' Effective May 23, Reflecting Strategic Pivot Via Proposed Merger With Bitcoin-Focused Nakamoto

Instil And ImmuneOnco To Present Clinical Trial Updates And Insights On PD-(L)1xVEGF At ASCO Meeting

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses
New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors
Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer
SAN DIEGO and CALGARY, AB, May 23, 2025 /PRNewswire/ -- Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.

ONCY

TSX:ONC

Oncolytics Biotech To Present New Data From Phase I/II GOBLET Clinical Trial At 2025 ASCO Annual Meeting

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced that PEMGARDA&#xAE; (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network&#xAE; (NCCN&#xAE;) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart.
This inclusion in the NCCN Guidelines recognizes PEMGARDA as a potential option for PrEP against COVID-19 in patients with B-cell malignancies. Immunocompromised patients may not mount an adequate immune response to vaccination.

Comments

Phathom Pharmaceuticals

Phathom Pharmaceuticals (PHAT) オプション

Phathom Pharmaceuticals (NASDAQ:PHAT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル